A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

March 31, 2029

Conditions
IgA Nephropathy
Interventions
BIOLOGICAL

SCTC21C

Drug: SCTC21C Administered SC

Trial Locations (20)

Unknown

The First Affiliated Hospital of Baotou Medical College, Baotou

Beijing Tsinghua Changgung Hospital, Beijing

Peking University First Hospital, Beijing

Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital, Chengdu

Guangdong Provincial People's Hospital, Guangzhou

The First Affliated Hospital, Zhejiang University School of Medicine, Hangzhou

Zhejiang Provincial People's Hospital, Hangzhou

Shandong Provincial Hospital, Jinan

The First Affiliated Hospital of Nanchang University, Nanchang

The Second Affiliated Hospital of Nanchang University, Nanchang

Guangxi Zhuang Autonomous Region People's Hospital, Nanning

Ningbo NO.2 Hospital, Ningbo

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Shanghai General Hospital, Shanghai

Wuxi People's Hospital, Wuxi

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an

The First Affiliated Hospital of Xiamen University, Xiamen

The Second Affiliated Hospital of Xingtai Medical College, Xingtai

Yantai Yuhuangding Hospital, Yantai

General Hospital of Ningxia Medical University, Yinchuan

All Listed Sponsors
lead

Sinocelltech Ltd.

INDUSTRY